title: Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
abstract: The combination of docetaxel and gemcitabine is frequently used to treat recurrent bone sarcoma. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is less toxic and more active than docetaxel or paclitaxel for breast cancer patients. The combination of nab-paclitaxel and gemcitabine has preclinical synergy and is approved to treat pancreatic cancer. We observed growth inhibition and improved survival with nab-paclitaxel in a Ewing sarcoma xenograft, and activity was additive with gemcitabine in an osteosarcoma model. Primary Ewing sarcoma tumors expressed the transport protein SPARC, previously associated with nab-paclitaxel activity. These findings provide rationale for further evaluation of nab-paclitaxel with gemcitabine for bone sarcoma.
authors.affiliation: Division of Pediatric Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
authors.forename: Lars M
authors.initials: LM
authors.lastname: Wagner
authors.forename: Hong
authors.initials: H
authors.lastname: Yin
authors.forename: David
authors.initials: D
authors.lastname: Eaves
authors.forename: Mark
authors.initials: M
authors.lastname: Currier
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Cripe
mesh_terms: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002648:Child; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D051379:Mice; D053758:Nanoparticles; D015676:Osteonectin / Q000032:analysis; D012516:Osteosarcoma / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D012512:Sarcoma, Ewing / Q000188:drug therapy
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D015676:Osteonectin; C577241:SPARC protein, human; D017239:Paclitaxel
keywords: Abraxane; Cav-1; Ewing sarcoma; SPARC; nab-paclitaxel; osteosarcoma